8-K: Teknova Q3 2025 Revenue Up 9%, Reaffirms Full-Year Guidance

Alpha Teknova, Inc. reported a 9% year-over-year revenue increase to $10.5 million for Q3 2025, marking its fifth consecutive quarter of growth, and reaffirmed its full-year revenue guidance.

Summary

• Total revenue for the third quarter ended September 30, 2025, was $10.5 million, representing a 9% increase compared to $9.6 million in the third quarter of 2024.
• This marks the fifth consecutive quarter of year-over-year revenue growth.
• Lab Essentials revenue grew by 16% to $8.3 million in Q3 2025, up from $7.2 million in Q3 2024.
• Clinical Solutions revenue decreased by 13% to $1.7 million in Q3 2025, down from $2.0 million in Q3 2024.
• Gross profit for Q3 2025 was $3.2 million, resulting in a gross margin of 30.7%, a significant improvement from $0.1 million and 0.9% in Q3 2024.
• The improvement in gross profit and margin was primarily due to the absence of $2.8 million in non-recurring and non-cash charges related to inventory disposal and write-downs in Q3 2024.
• Operating expenses decreased to $7.2 million in Q3 2025 from $7.5 million in Q3 2024, driven by a net reduction in general and administrative spending.
• Net loss for Q3 2025 was $4.3 million, or negative $0.08 per diluted share, an improvement from a net loss of $7.6 million, or negative $0.15 per diluted share, in Q3 2024.
• Adjusted EBITDA for Q3 2025 was negative $1.6 million, an improvement from negative $5.0 million in Q3 2024.
• Free Cash Outflow for Q3 2025 was $2.4 million, consistent with Q3 2024.
• Total cash and short-term investments stood at $22.1 million, and total borrowings were $13.2 million at the end of Q3 2025.
• The company reaffirmed its fiscal 2025 revenue guidance of $39 million to $42 million.
• The company also reiterated its anticipation of Free Cash Outflow of less than $12 million for fiscal year 2025.

Sentiment

Score: 7

Explanation: The company demonstrated solid revenue growth, significant improvement in gross profit and net loss, and reaffirmed its full-year guidance despite a challenging biotech funding environment. While Clinical Solutions revenue declined, the strength in Lab Essentials and overall operational improvements are positive indicators. The continued Free Cash Outflow and net loss are areas for ongoing monitoring.

Positives

• Achieved 9% year-over-year revenue growth in Q3 2025, reaching $10.5 million.
• Marked the fifth consecutive quarter of year-over-year revenue growth.
• Lab Essentials revenue grew significantly by 16% to $8.3 million, demonstrating strong performance in this segment.
• Gross profit improved substantially to $3.2 million (30.7% margin) from $0.1 million (0.9% margin) in the prior year, largely due to the absence of non-recurring charges.
• Operating expenses decreased to $7.2 million from $7.5 million, driven by reduced general and administrative spending, indicating cost management efforts.
• Net loss significantly narrowed to $4.3 million (negative $0.08 per diluted share) from $7.6 million (negative $0.15 per diluted share) in Q3 2024.
• Adjusted EBITDA improved to negative $1.6 million from negative $5.0 million in Q3 2024, showing progress towards profitability.
• Free Cash Outflow remained flat year-over-year at $2.4 million, despite revenue growth, suggesting improved cash management relative to operations.
• Reaffirmed full-year 2025 revenue guidance of $39-42 million and Free Cash Outflow of less than $12 million, indicating confidence in future performance.
• The number of Clinical Solutions customers continues to rise despite a challenging funding backdrop for smallto mid-size biotech companies.

Negatives

• Clinical Solutions revenue decreased by 13% to $1.7 million in Q3 2025 compared to Q3 2024, indicating weakness in this segment.
• The company continues to report a net loss of $4.3 million and negative Adjusted EBITDA of $1.6 million, indicating ongoing unprofitability.
• Total cash and short-term investments decreased to $22.1 million at September 30, 2025, from $30.396 million at December 31, 2024, reflecting cash burn.
• Total assets decreased to $107.625 million at September 30, 2025, from $118.769 million at December 31, 2024.
• Stockholders' equity decreased to $72.650 million at September 30, 2025, from $82.394 million at December 31, 2024.
• The company continues to experience Free Cash Outflow, totaling $2.4 million for the quarter and $8.984 million for the nine months ended September 30, 2025.

Risks

• Demand for products, including the potential delay to or pausing of customer orders.
• Assessment of fundamental indicators of future demand across its target customer base.
• Cash flows and revenue growth rate.
• Supply chain, sourcing, manufacturing, and warehousing challenges.
• Inventory management issues.
• Risks related to global economic and marketplace uncertainties, including those related to the conflicts in Ukraine and the Middle East.
• Potential acquisitions and integration of other companies.
• Other factors discussed in the Risk Factors section of Teknova's most recent periodic reports filed with the Securities and Exchange Commission (SEC), including in its Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q.

Future Outlook

The company reaffirms its fiscal 2025 outlook, anticipating total revenue between $39 million and $42 million and Free Cash Outflow of less than $12 million. Management believes its relationships with Clinical Solutions customers and diverse Lab Essentials product portfolio position it for long-term, sustainable, above-market growth.

Management Comments

• "We had a strong third quarter, our fifth consecutive quarter of year-over-year revenue growth, despite a very challenging funding backdrop for smallto mid-size biotech companies." Stephen Gunstream, President and Chief Executive Officer.
• "Notwithstanding those challenges, the number of our Clinical Solutions customers continues to rise. We believe that our relationships with those customers, paired with our diverse Lab Essentials product portfolio and customer base, position us for long-term, sustainable, above-market growth." Stephen Gunstream, President and Chief Executive Officer.
• "Compared to 2024, we delivered 9% revenue growth in the third quarter 2025, while Adjusted EBITDA improved and Free Cash Outflow was the same as last year." Matt Lowell, Chief Financial Officer.
• "The Company is performing well operationally, and revenue from sales of our Lab Essentials products more than offset lagging Clinical Solutions sales." Matt Lowell, Chief Financial Officer.
• "We therefore reiterate our 2025 revenue guidance of $39-42 million, while we continue to anticipate full-year Free Cash Outflow of less than $12 million." Matt Lowell, Chief Financial Officer.

Industry Context

The company operates in the life sciences industry, providing critical reagents for molecular diagnostics, synthetic biology, and emerging therapeutic modalities. Management notes a "challenging funding backdrop for smallto mid-size biotech companies," which likely impacts its Clinical Solutions segment, but highlights the rising number of Clinical Solutions customers and the strength of its Lab Essentials portfolio as mitigating factors. The focus on customizable solutions and scaling from RUO to GMP suggests alignment with industry needs for flexibility and quality in research and development.

Stakeholder Impact

• Shareholders: Positive impact from revenue growth, improved profitability metrics (gross profit, net loss, Adjusted EBITDA), and reaffirmed guidance, suggesting stability and progress. However, continued net losses and cash outflow may concern some.
• Customers: Continued growth in Clinical Solutions customer numbers and a diverse Lab Essentials product portfolio indicate ongoing value and service.
• Employees: Operational performance improvements and strategic positioning for "long-term, sustainable, above-market growth" could imply job security and potential for future opportunities.

Next Steps

• Attend Craig-Hallum 16th Annual Alpha Select Conference on November 18, 2025.
• Attend Stephens Annual Investment Conference 2025 on November 19, 2025.
• Attend Piper Sandler 37th Annual Healthcare Conference on December 4, 2025.
• Host a webcast and conference call on Thursday, November 6, 2025, beginning at 5:00 p.m. Eastern Time to discuss the financial results.

Key Dates

Recommendation

While the company shows positive operational improvements, including revenue growth, better gross margins, and reduced net loss, it continues to operate at a net loss and negative Adjusted EBITDA, with ongoing Free Cash Outflow. The reaffirmation of guidance suggests stability, but the challenging funding environment for biotech and the decline in Clinical Solutions revenue present headwinds. The stock is not a strong buy due to continued unprofitability and cash burn, but the operational improvements and growth in Lab Essentials suggest it's not a sell either. A "Hold" recommendation allows investors to monitor the company's progress in achieving profitability and positive cash flow, especially given the challenging industry backdrop.

Keywords

Alpha Teknova, TKNO, financial results, Q3 2025, revenue growth, Lab Essentials, Clinical Solutions, biotech, reagents, molecular diagnostics, synthetic biology, therapeutics, EBITDA, Free Cash Flow, earnings report